Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1453-1460

  Yue, Lu ^a   Wang, Ying ^b   Wang, Huamao ^c   Gao, Huiping ^c   Liang, Jun ^a   Sui, Aihua ^a   Xiang, Jinyu ^a   Zhou, Fang ^a   Xu, Congcong ^a   Zhao, Wenwen ^a   Liang, Wanhua ^a   Yao, Ruyong ^a  

^a QINGDAO UNIVERSITY   (China)

^b SHANGHAI XUHUI CENTRAL HOSPITAL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

4F2; Apoptosis; Doxorubicin; HCC; IGF IR

Indexed keywords

DOXORUBICIN; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4F2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER INHIBITION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84866439860     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1960     Document Type: Article

References (38)

1. Baserga R, Peruzzi F and Reiss K: The IGF-1 receptor in cancer biology. Int J Cancer 107: 873-877, 2003.
2. Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12: 159-169, 2012.
3. Kaiser U, Schardt C, Brandscheidt D, Wollmer E and Havemann K: Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol 119: 665-668, 1993.
4. Parker AS, Cheville JC, Janney CA and Cerhan JR: High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum Pathol 33: 801-805, 2002.
5. Pekonen F, Nyman T, Ilvesmaki V and Partanen S: Insulin-like growth factor binding proteins in human breast cancer tissue. Cancer Res 52: 5204-5207, 1992.
6. Resnik JL, Reichart DB, Huey K, Webster NJ and Seely BL: Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 58: 1159-1164, 1998.
7. Steller MA, Delgado CH, Bartels CJ, Woodworth CD and Zou Z: Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 56: 1761-1765, 1996.
8. Werner H, Re GG, Drummond IA, et al: Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA 90: 5828-5832, 1993.
9. Breuhahn K and Schirmacher P: Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol 14: 1690-1698, 2008.
10. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998.
11. Vadgama JV, Wu Y, Datta G, Khan H and Chillar R: Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57: 330-340, 1999.
12. Boulle N, Logie A, Gicquel C, Perin L and Le Bouc Y: Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 83: 1713-1720, 1998.
13. Martin DM, Singleton JR, Meghani MA and Feldman EL: IGF receptor function and regulation in autocrine human neuroblastoma cell growth. Regul Pept 48: 225-232, 1993.
14. Reeve AE, Eccles MR, Wilkins RJ, Bell GI and Millow LJ: Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature 317: 258-260, 1985.
15. Sohda T, Iwata K, Soejima H, Kamimura S, Shijo H and Yun K: In situ detection of insulin-like growth factor II (IGF2) and H19 gene expression in hepatocellular carcinoma. J Hum Genet 43: 49-53, 1998.
16. Takeda S, Kondo M, Kumada T, et al: Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease. Oncogene 12: 1589-1592, 1996.
17. Zhang L, Zhou W, Velculescu VE, et al: Gene expression profiles in normal and cancer cells. Science 276: 1268-1272, 1997.
18. Breuhahn K, Longerich T and Schirmacher P: Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25: 3787-3800, 2006.
19. Wilkin F, Gagne N, Paquette J, Oligny LL and Deal C: Pediatric adrenocortical tumors: molecular events leading to insulin-like growth factor II gene overexpression. J Clin Endocrinol Metab 85: 2048-2056, 2000.
20. Denley A, Brierley GV, Carroll JM, et al: Differential activation of insulin receptor isoforms by insulin-like growth factors is determined by the C domain. Endocrinology 147: 1029-1036, 2006.
21. Adams TE, Epa VC, Garrett TP and Ward CW: Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57: 1050-1093, 2000.
22. Perer ES, Madan AK, Shurin A, et al: Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res 94: 1-5, 2000.
23. Burtrum D, Zhu Z, Lu D, et al: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63: 8912-8921, 2003.
24. Heron-Milhavet L, Karas M, Goldsmith CM, Baum BJ and LeRoith D: Insulin-like growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair. J Biol Chem 276: 18185-18192, 2001.
25. Kulik G, Klippel A and Weber MJ: Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 17: 1595-1606, 1997.
26. Jacobs S, Cook S, Svoboda ME and van Wyk JJ: Interaction of the monoclonal antibodies αIR-1 and αIR-3 with insulin and somatomedin-C receptors. Endocrinology 118: 223-226, 1986.
27. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS and Yee D: A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63: 627-635, 2003.
28. Cohen BD, Baker DA, Soderstrom C, et al: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063-2073, 2005.
29. Lu D, Zhang H, Koo H, et al: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280: 19665-19672, 2005.
30. Langone JJ: Applications of immobilized protein A in immunochemical techniques. J Immunol Methods 55: 277-296, 1982.
31. Pandini G, Vigneri R, Costantino A, et al: Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5: 1935-1944, 1999.
32. Scharf JG and Braulke T: The role of the IGF axis in hepato- carcinogenesis. Horm Metab Res 35: 685-693, 2003.
33. Benini S, Manara MC, Baldini N, et al: Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 7: 1790-1797, 2001.
34. Gooch JL, Tang Y, Ricono JM and Abboud HE: Insulin-like growth factor-I induces renal cell hypertrophy via a calcineurin-dependent mechanism. J Biol Chem 276: 42492-42500, 2001.
35. Turner BC, Haffty BG, Narayanan L, et al: Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57: 3079-3083, 1997.
36. Nakamura S, Watanabe H, Miura M and Sasaki T: Effect of the insulin-like growth factor I receptor on ionizing radiation-induced cell death in mouse embryo fibroblasts. Exp Cell Res 235: 287-294, 1997.
37. Sell C, Baserga R and Rubin R: Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 55: 303-306, 1995.
38. Dunn SE, Hardman RA, Kari FW and Barrett JC: Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 57: 2687-2693, 1997.